Just scroll to the very bottom and hit play in the audio player below this article ☟ to enjoy listening to the full radio interview with Sara.
Virofend’s Sara Cuadrado‑Castaño Takes Center Stage on Radio Vive! Salamanca
Radio Vive! Salamanca welcomed Sara Cuadrado‑Castaño — founder, CEO and Principal Investigator at ViroFend Therapeutics S.L. — for a lively conversation about her latest oncolytic virus–based immunotherapy research and the company’s mission to turn engineered viruses into precision weapons against cancer.
During the broadcast, Sara outlined several projects focused on viruses that selectively infect and destroy tumour cells while kick‑starting a systemic immune response. She highlighted:
- A new library of armed oncolytic adenoviruses and paramyxoviruses designed to replicate only inside malignant tissue and to express immune‑stimulating transgenes.
- Partnerships with Spanish cancer centres and EU immuno‑oncology consortia that are fast‑tracking IND‑enabling studies and sharing real‑time translational data.
- A first‑in‑human phase I/II proof‑of‑concept trial slated for early 2026, aimed at patients with refractory solid tumours.
The Vive! Radio team also surprised Sara with congratulations on her recent appointment as town crier (“pregonera”) for the 2025 Salamanca Fairs and Festivals — an honor reserved for citizens who leave a significant cultural or scientific mark on the city. Sara thanked the hosts, noting that “science thrives when it’s woven into the fabric of the community.”
Stay tuned for more news as ViroFend Therapeutics advances the next generation of oncolytic virus immunotherapies.
